Mobile

A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcut...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003973-16

A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of repeated subcutaneous (s.c.) injections of 150µg CAD106 in patients with mild Alzheimer's Disease over the 52 weeks of the study.

Critère d'inclusion

  • MILD ALZHEIMER’S DISEASE

Liens